Published in Blood on December 20, 2012
Developments in Viral Vector-Based Vaccines. Vaccines (Basel) (2014) 0.94
Lentiviral vectors for cancer immunotherapy and clinical applications. Cancers (Basel) (2013) 0.93
Practical considerations in gene therapy for HIV cure. Curr HIV/AIDS Rep (2014) 0.88
Construction of stable packaging cell lines for clinical lentiviral vector production. Sci Rep (2015) 0.82
Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy. PLoS One (2014) 0.81
Gene therapy strategies to exploit TRIM derived restriction factors against HIV-1. Viruses (2014) 0.81
Engineering T Cells to Functionally Cure HIV-1 Infection. Mol Ther (2015) 0.81
Hematopoietic stem cell transplantation for HIV cure. J Clin Invest (2016) 0.81
An efficient large-scale retroviral transduction method involving preloading the vector into a RetroNectin-coated bag with low-temperature shaking. PLoS One (2014) 0.81
Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice. J Virol (2015) 0.80
Gene therapy strategies for HIV/AIDS: preclinical modeling in humanized mice. Viruses (2013) 0.80
Bone Marrow Gene Therapy for HIV/AIDS. Viruses (2015) 0.79
RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope. Mol Ther Methods Clin Dev (2016) 0.79
Progress toward curing HIV infection with hematopoietic cell transplantation. Stem Cells Cloning (2015) 0.78
A quantitative comparison of anti-HIV gene therapy delivered to hematopoietic stem cells versus CD4+ T cells. PLoS Comput Biol (2014) 0.78
Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus. PLoS Pathog (2016) 0.77
HIV gene therapy research advances. Blood (2013) 0.76
Exploiting Genetic Interference for Antiviral Therapy. PLoS Genet (2016) 0.76
Conditional Cytotoxic Anti-HIV Gene Therapy for Selectable Cell Modification. Hum Gene Ther (2016) 0.75
Glycosyl-phosphatidylinositol (GPI)-anchored anti-HIV scFv efficiently protect CD4 T cells from HIV-1 infection and deletion in hu-PBL mice. J Virol (2016) 0.75
Perspectives of Genome-Editing Technologies for HIV Therapy. Curr HIV Res (2016) 0.75
CD4(+) T Cells Modified by the Endoribonuclease MazF Are Safe and Can Persist in SHIV-infected Rhesus Macaques. Mol Ther Nucleic Acids (2014) 0.75
Cell-based gene therapy against HIV. Gene Ther (2015) 0.75
New Drugs in the Pipeline for the Treatment of HIV: a Review. Curr Infect Dis Rep (2017) 0.75
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 13.55
Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol (1998) 8.21
Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med (1995) 6.90
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med (2001) 5.33
Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A (2006) 4.23
The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest (2009) 3.34
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol (2005) 2.97
Genetic therapies against HIV. Nat Biotechnol (2007) 2.50
Optimization of methods to assess human mucosal T-cell responses to HIV infection. J Immunol Methods (2003) 2.32
Resistance of mature T cells to oncogene transformation. Blood (2008) 2.32
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood (2000) 2.15
Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS (2003) 2.05
Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther (2009) 1.97
Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med (2002) 1.93
Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy. Blood (2009) 1.88
A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther (2002) 1.83
Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther (2004) 1.80
Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med (2002) 1.80
Estimating the benefit of an HIV-1 vaccine that reduces viral load set point. J Infect Dis (2007) 1.41
Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med (2004) 1.41
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis (2006) 1.37
Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. J Virol (2003) 1.34
Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J Gene Med (2004) 1.29
A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc Natl Acad Sci U S A (1996) 1.27
A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102. J Acquir Immune Defic Syndr (2006) 1.06
Impact of gene-modified T cells on HIV infection dynamics. J Theor Biol (2005) 1.01
Mixed models for assessing correlation in the presence of replication. J Air Waste Manag Assoc (2003) 1.01
Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection. PLoS One (2010) 0.99
Virological failure and adherence to antiretroviral therapy in HIV-infected patients. AIDS (1998) 0.97
The role of TCR specificity and clonal competition during reconstruction of the peripheral T cell pool. J Immunol (2009) 0.91
HIV sequence variation associated with env antisense adoptive T-cell therapy in the hNSG mouse model. Mol Ther (2010) 0.88
T cell receptor contact to restricting MHC molecules is a prerequisite for peripheral interclonal T cell competition. J Exp Med (2008) 0.84
Secreted antiviral entry inhibitory (SAVE) peptides for gene therapy of HIV infection. Mol Ther (2011) 0.83
Peaceful coexistence or clonal dominance? Blood (2009) 0.81
QIIME allows analysis of high-throughput community sequencing data. Nat Methods (2010) 85.34
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Linking long-term dietary patterns with gut microbial enterotypes. Science (2011) 17.30
PyNAST: a flexible tool for aligning sequences to a template alignment. Bioinformatics (2009) 15.93
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42
Short pyrosequencing reads suffice for accurate microbial community analysis. Nucleic Acids Res (2007) 9.15
Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell (2008) 8.41
Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol (2004) 8.27
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
Minimum information about a marker gene sequence (MIMARKS) and minimum information about any (x) sequence (MIxS) specifications. Nat Biotechnol (2011) 7.53
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature (2010) 6.95
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res (2007) 6.89
Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol (2011) 6.73
The CD28 signaling pathway regulates glucose metabolism. Immunity (2002) 6.65
siRNA-directed inhibition of HIV-1 infection. Nat Med (2002) 6.36
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (2010) 5.79
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
The macaque gut microbiome in health, lentiviral infection, and chronic enterocolitis. PLoS Pathog (2008) 5.28
Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol (2002) 5.10
Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. BMC Microbiol (2010) 4.97
In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature (2011) 4.81
Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med (2011) 4.78
HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res (2007) 4.72
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 4.58
Standardization of cytokine flow cytometry assays. BMC Immunol (2005) 4.55
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A (2006) 4.23
Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science (2012) 4.20
Identification of upper airway anatomic risk factors for obstructive sleep apnea with volumetric magnetic resonance imaging. Am J Respir Crit Care Med (2003) 4.14
Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol (2008) 3.92
Bayesian community-wide culture-independent microbial source tracking. Nat Methods (2011) 3.88
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant (2010) 3.79
Global landscape of HIV-human protein complexes. Nature (2011) 3.70
Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog (2006) 3.67
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med (2005) 3.65
Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2010) 3.54
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol (2002) 3.46
Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol (2002) 3.43
The human gut virome: inter-individual variation and dynamic response to diet. Genome Res (2011) 3.32
The working hours of hospital staff nurses and patient safety. Health Aff (Millwood) (2004) 3.31
Unintended effects of a computerized physician order entry nearly hard-stop alert to prevent a drug interaction: a randomized controlled trial. Arch Intern Med (2010) 3.31
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria. Nature (2013) 3.21
Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity (2009) 3.21
Selection of target sites for mobile DNA integration in the human genome. PLoS Comput Biol (2006) 3.21
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol (2006) 3.03
Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther (2007) 2.99
Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J Leukoc Biol (2002) 2.93
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood (2004) 2.90
CARs on track in the clinic. Mol Ther (2011) 2.86
Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 2.84
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med (2015) 2.77